To evaluate long-term efficacy of intravitreal bevacizumab (IVB) versus combined IVB and macular grid laser photocoagulation for the treatment of macular edema secondary to branch retinal vein occlusion (BRVO).
Methods
In this prospective study, 18 eyes were randomized into 2 groups according to treatment: Group 1 (9 eyes) underwent IVB at baseline, at month 1, and at month 2; Group 2 (9 eyes) underwent same IVB protocol combined with macular grid laser photocoagulation. Macular edema and visual acuity represented the endpoints of the study. IVB reinjections were performed in both groups if recurrent macular edema was diagnosed. Spectral domain optical coherence tomography examination as well as visual acuity examination were performed during follow-up. Statistical evaluation was performed for a matched-pair analysis.
Results
In Group 1, median baseline central retinal thickness (CRT) decreased from 420 μm (95% confidence interval 355.6-484.4) to 323 μm (261.44-384.56) at month 12 (p=0.06); median baseline BCVA improved from 0.7 logMAR (0.54-0.86) to 0.4 logMAR (0.29-0.51) at month 12 (p<0.01). In Group 2, baseline CRT decreased from 386 μm (353.91-418.09) to 238 μm (200.58-275.42) at month 12 (p<0.01); median BCVA improved from 0.6 logMAR (0.45-0.75) to 0.2 logMAR (0.12-0.28) at month 12 (p<0.01). A statistically significant difference (p=0.03) was found regarding the median number of injections (Group 1: 4±1.1; Group 2: 3±0.4).
Conclusions
Both treatment modalities appeared effective to control BRVO-induced macular edema. In the combined-treatment Group, we observed a lower number of reinjections during follow-up, suggesting the efficacy of grid laser photocoagulation to reduce the number of intravitreal injections and maintain short- and long-term results of the therapy.
ShroffD., MehtaD.K., AroraR., NarulaR., ChauhanD.Natural history of macular status in recent-onset branch retinal vein occlusion: an optical coherence tomography study.Int Ophthalmol2008; 28: 261–8.
The Branch Vein Occlusion Study Group.Argon laser photocoagulation for macular edema in branch vein occlusion.Am J Ophthalmol1984; 98: 271–82.
5.
Battaglia ParodiM., SavianoS., RavalicoG.Grid laser treatment in macular branch retinal vein occlusion.Graefes Arch Clin Exp Ophthalmol1999; 237: 1024–7.
6.
McIntoshR.L., MohamedQ., SawS.M., WongT.Y.Interventions for branch retinal vein occlusion: an evidence-based systematic review.Ophthalmology2007; 114: 835–54.
7.
BadalàF.The treatment of branch retinal vein occlusion with bevacizumab.Curr Opin Ophthalmol2008; 19: 234–8.
8.
StahlA., StruebinI., HansenL.L., AgostiniH.T., FeltgenN.Bevacizumab in central retinal vein occlusion: a retrospective analysis after 2 years of treatment.Eur J Ophthalmol2010; 20: 180–5.
9.
GregoriN.Z., RattanG.H., RosenfeldP.J.Safety and efficacy of intravitreal bevacizumab (Avastin) for the management of branch and hemiretinal vein occlusion.Retina2009; 29: 913–25.
10.
PragerF., MichelsS., KriechbaumK.Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial.Br J Ophthalmol2009; 93: 452–6.
11.
KondoM., KondoN., ItoY.Intravitreal injection of bevacizumab for macular edema secondary to branch retinal vein occlusion: results after 12 months and multiple regression analysis.Retina2009; 29: 1242–8.
12.
JaissleG.B., LeitritzM., GeliskenF., ZiemssenF., Bartz-SchmidtK.U., SzurmanP.One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion.Graefes Arch Clin Exp Ophthalmol2009; 247: 27–33.
13.
Salinas-AlamánA., Zarranz-VenturaJ., Caire González-JaureguiJ.M.Intravitreal bevacizumab associated with grid laser photocoagulation in macular edema secondary to branch retinal vein occlusion.Eur J Ophthalmol2011; 21: 434–9.
14.
ChungE.J., HongY.T., LeeS.C., KwonO.W., KohH.J.Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion.Graefes Arch Clin Exp Ophthalmol2008; 246: 1241–7.
15.
StahlA., AgostiniH., HansenL.L., FeltgenN.Bevacizumab in retinal vein occlusion-results of a prospective case series.Graefes Arch Clin Exp Ophthalmol2007; 245: 1429–36.
16.
CostaR.A., JorgeR., CalucciD., MeloL.A.Jr, CardilloJ.A., ScottI.U.Intravitreal bevacizumab (Avastin) for central and hemicentral retinal vein occlusions: IBeVO study.Retina2007; 27: 141–9.
17.
RabenaM.D., PieramiciD.J., CastellarinA.A., NasirM.A., AveryR.L.Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion.Retina2007; 27: 419–25.
18.
BrownD.M., CampochiaroP.A., BhisitkulR.B.Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study.Ophthalmology2011; 118: 1594–602.
19.
CampochiaroP.A., HeierJ.S., FeinerL.; BRAVO Investigators. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study.Ophthalmology2010; 117: 1102–12.
20.
WroblewskiJ.J., WellsJ.A.III, GonzalesC.R.Pegaptanib sodium for macular edema secondary to branch retinal vein occlusion.Am J Ophthalmol2010; 149: 147–54.
ScottI.U., IpM.S., VanVeldhuisenP.C.; SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6.Arch Ophthalmol2009; 127: 1115–28.
23.
ByunY.J., RohM.I., LeeS.C., KohH.J.Intravitreal triamcinolone acetonide versus bevacizumab therapy for macular edema associated with branch retinal vein occlusion.Graefes Arch Clin Exp Ophthalmol2010; 248: 963–71.
24.
GuthoffR., MeigenT., HennemannK., SchraderW.Comparison of bevacizumab and triamcinolone for treatment of macular edema secondary to branch retinal vein occlusion in a pair-matched analysis.Ophthalmologica2010; 224: 319–24.
25.
TaoY., HouJ., JiangY.R., LiX.X., JonasJ.B.Intravitreal bevacizumab vs triamcinolone acetonide for macular oedema due to central retinal vein occlusion.Eye2010; 24: 810–5.
26.
KaushikS., GuptaV., GuptaA., DograM.R., SinghR.Intractable glaucoma following intravitreal triamcinolone in central retinal vein occlusion.Am J Ophthalmol2004; 137: 758–60.
27.
HallerJ.A., BandelloF., BelfortR.Jr; Ozurdex GENEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.Ophthalmology2010; 117: 1134–46.
28.
MandelcornM.S., NrusimhadevaraR.K.Internal limiting membrane peeling for decompression of macular edema in retinal vein occlusion: a report of 14 cases.Retina2004; 24: 348–55.
29.
MesterU., DillingerP.Vitrectomy with arteriovenous decompression and internal limiting membrane dissection in branch retinal vein occlusion.Retina2002; 22: 740–6.
30.
García-ArumíJ., Martinez-CastilloV., BoixaderaA., BlascoH., CorcosteguiB.Management of macular edema in branch retinal vein occlusion with sheathotomy and recombinant tissue plasminogen activator.Retina2004; 24: 530–40.
31.
FekratS., GoldbergM.F., FinkelsteinD.Laser-induced chorioretinal venous anastomosis for nonischemic central or branch retinal vein occlusion.Arch Ophthalmol1998; 116: 43–52.
32.
WeissJ.N., BynoeL.A.Injection of tissue plasminogen activator into a branch retinal vein in eyes with central retinal vein occlusion.Ophthalmology2001; 108: 2249–57.
RieseJ., LoukopoulosV., MeierC., TimmermannM., GerdingH.Combined intravitreal triamcinolone injection and laser photocoagulation in eyes with persistent macular edema after branch retinal vein occlusion.Graefes Arch Clin Exp Ophthalmol2008; 246: 1671–6.
35.
CakirM., DoganM., BayraktarZ.Efficacy of intravitreal triamcinolone for the treatment of macular edema secondary to branch retinal vein occlusion in eyes with or without grid laser photocoagulation.Retina2008; 28: 465–72.
36.
ParodiM.B., IaconoP., RavalicoG.Intravitreal triamcinolone acetonide combined with subthreshold grid laser treatment for macular oedema in branch retinal vein occlusion: a pilot study.Br J Ophthalmol2008; 92: 1046–50.
37.
AielloL.P., AveryR.L., ArriggP.G.Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.N Engl J Med1994; 331: 1480–7.
38.
MatsumotoY., FreundK.B., PeirettiE., CooneyM.J., FerraraD.C., YannuzziL.A.Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease.Retina2007; 27: 426–31.
